Posts Tagged ‘AGEN’

Daily Pharma Watch

July 27th, 2010

Antigenics Inc. (AGEN):

This morning Antigenics announced positive results from their Phase I clinical trial in herpes patients. The company was testing their developmental vaccine AG-707 on 35 herepes positive patients. The company noted that the patients who received the vaccine showed a statistically significant CD4+ T Cell response and a majority also showed a CD8+T Cell response. CD4+ cells are also known as helper cells because assist other white blood cells in the immunologic processes, while CD8+ cells are known as Cytotoxic cells because they destroy virally infected cells and tumor cells. » Read more: Daily Pharma Watch

No comments »

Posted in Uncategorized

Tags:

Antigenics Inc. (AGEN): Trial Data Analysis

May 20th, 2010

Antigenics Inc. (AGEN):

I hae received a lot of email asking why the shares of Antigenics are down this morning on the release of their data for Oncophage, so I’ll do my best to give my honest opinion as to what is happening. » Read more: Antigenics Inc. (AGEN): Trial Data Analysis

1 comment »

Posted in Antigenics

Tags:

Daily Pharma Watch

May 20th, 2010

Geron (GERN):

Geron said this morning that they have seen positive data in an animal model of their small molecule telomerase activator TAT153 in idiopathic pulmonary fibrosis (IPF). The data looked positive and showed that TAT153 reduced inflammation, preserved lung function and slowed progression of the disease in the model. However, the drug is several years out in development, but there are currently not many options out there for patients of IPF and a new treatment hasn’t been approved for over 50 years. » Read more: Daily Pharma Watch

No comments »

Posted in Uncategorized

Tags: